Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus - Wikidata - wikimedia - TriplyDB

Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus

Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus

http://www.wikidata.org/entity/Q35164008

about

Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance Hepatitis C Virus and Antiviral Drug Resistance HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors Casein kinase II inhibitor enhances production of infectious genotype 1a hepatitis C virus (H77S)Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix α18 Hepatitis C Virus Indirectly Disrupts DNA Damage-Induced p53 Responses by Activating Protein Kinase R.hnRNP L and NF90 interact with hepatitis C virus 5'-terminal untranslated RNA and promote efficient replication NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains.Rad51 Interacts with Non-structural 3 Protein of Hepatitis C Virus and Regulates Viral Production Antiviral drug resistance as an adaptive process Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation.Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Hepatitis C virus NS3 mutations in haemophiliacs Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model A subclone of HuH-7 with enhanced intracellular hepatitis C virus production and evasion of virus related-cell cycle arrest.Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77.Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients Regulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain III.miR-122 stimulates hepatitis C virus RNA synthesis by altering the balance of viral RNAs engaged in replication versus translation Functionally conserved architecture of hepatitis C virus RNA genomes.Dissecting the roles of the 5' exoribonucleases Xrn1 and Xrn2 in restricting hepatitis C virus replication.Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex.SEC14L2 enables pan-genotype HCV replication in cell culture.Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease.Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.Base pairing between hepatitis C virus RNA and microRNA 122 3' of its seed sequence is essential for genome stabilization and production of infectious virus.Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system.Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort.Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 in regulation of hepatitis C virus replication.Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication CD4+ T-cell recovery with suppressive ART-induced rapid sequence evolution in hepatitis C virus envelope but not NS3.Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b.

P2860

Q26777408-FCAAF4B2-AB10-44BD-8708-BA917D5AEC44 Q27469038-DA28D4E4-BC37-4327-8E7D-5C5227F40CCA Q28067295-F9B20A63-9FAF-4829-AF2F-D01DC81AEC9D Q28481038-F6113F71-152D-4E77-AB9D-66D78F5F120D Q28542410-5E2349AA-822E-4F32-ACF0-3F980B1C7296 Q30383665-4BDF3365-820D-4B59-B907-616A9B576745 Q33603822-DB3CF1AF-2033-41BF-A03D-6CFE7F94A380 Q33744088-121E469C-8F93-4E1F-AC9A-35B285C86320 Q33778857-CF56667A-2AD9-4F4F-8758-4191625DECA5 Q33875390-6C7E3959-AFE1-4821-ABC1-D33DC73B4D2D Q33878407-216CFF9E-51B9-439F-A218-07DB1129D09D Q33934312-11B7117C-707E-40A9-948C-AE6D363C88E9 Q34020915-BD092AC1-C786-477B-85B2-A0A86724CC97 Q34035703-A4D4793A-CE4F-4C43-B3C4-7BC1FF2212D9 Q34111759-A850BB41-B857-40FD-BC65-BC4A5893E45D Q34298877-486E2981-44AC-4E41-A965-5DA30C450616 Q34334375-C39118C2-2641-4F66-B706-E5FD2E8791BC Q34534451-4F643B0D-4FD1-48DA-91E5-3BEAE2C29E65 Q34599453-6E069E66-84BF-4C52-86CF-D71A9C2725A8 Q34992715-E09C5E4B-B9D3-49F3-80B6-436BC0D906C5 Q35077010-407A02AB-C40F-4E18-9D2E-EFBDA904B278 Q35077458-AF8DD81E-0744-4671-8BD6-C1360EB01239 Q35079438-EB1ADB32-22A3-427B-8B13-83E490BDDE51 Q35229364-DD9BD723-7BAA-476F-AF63-493929478F5C Q35488499-DB684484-7A29-421B-83F7-775772D2EAB4 Q35735135-8D7A7401-CD09-48DD-AFC5-90AE67BFA07F Q35743753-9B9BED26-F85A-4DE8-B9D7-D1F1957AF197 Q35746343-E94AA60B-98A9-4836-84C3-98CBA3CD119E Q35783348-953BC6C4-9A26-4424-80E8-A6DA0A20E7B1 Q35867512-7562EDB8-C3B0-4446-BAB6-76B008AA5B4E Q35935502-374334F5-E4D4-4450-A2E6-C38FDA69F99B Q36155564-82781359-2B03-43EB-A6FF-2E9371EE94B8 Q36290778-9A76B978-DC68-4E08-AA8C-87F550631D72 Q36438628-77C62B13-5F6C-45E8-B976-4C0D505F1298 Q36506480-A5389B3A-342D-4425-A112-C35F37F1834E Q36583277-E2117CFB-A7B3-4E1A-B79B-6483D5C79E36 Q36612971-B9A4ADE0-8F45-43FC-A3BC-D2191DE2A214 Q36619647-CEFBCEFA-F237-4224-A3EF-CDD0C527EB71 Q36667066-EFC8E33E-78E5-4D95-ABE7-EE8B97DA4577 Q36670297-F8FCE0EC-8494-4C0D-8130-26EFBAB69B74

P2860

Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus

http://www.wikidata.org/entity/Q35164008

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Protease inhibitor-resistant h ...... production of infectious virus

@ast

Protease inhibitor-resistant h ...... production of infectious virus

@en

type

label

Protease inhibitor-resistant h ...... production of infectious virus

@ast

Protease inhibitor-resistant h ...... production of infectious virus

@en

prefLabel

Protease inhibitor-resistant h ...... production of infectious virus

@ast

Protease inhibitor-resistant h ...... production of infectious virus

@en

P1433

Q35164008-C042017B-EBFC-4315-96EA-746434D9DA93

P1476

Q35164008-E710EF07-5F01-48A8-AD1F-F137335CB42E

P2093

Q35164008-0A9677AE-AEE9-42B8-B7FC-62390978470A

Q35164008-46982A60-714B-4515-B66E-5B1B482B0EB6

Q35164008-59A38F8B-6A63-4CE8-BD72-A7DC5DF7D5C6

Q35164008-6D2EACA1-0D4B-4A6F-A250-F31C4611BC21

Q35164008-D9F54D6B-C312-4F54-852D-E5012C7E9899

Q35164008-DA0548AB-3B65-4D1A-8B45-9AFCDDE28964

P2860

Q35164008-0821ECD3-E34D-417B-89D2-6E1AD5320F47

Q35164008-0BF97EF4-6BB8-4531-982C-AD0408B22E31

Q35164008-12A40918-0511-456E-A2BC-D679EA07A38F

Q35164008-17D89279-7B35-4B4B-897E-6842F1FC2602

Q35164008-2F3FA638-8D26-4AA7-B1F5-0B549F60F750

Q35164008-3DD52B0C-A598-4BA6-BF4A-3CD21B7CE3EF

Q35164008-3EACB59E-6A44-4418-96AD-A93B7506D158

Q35164008-40D03932-3533-441D-8450-52E9CD3AB05C

Q35164008-4642EF04-5DB3-431B-ABEB-60BE3BA507A1

Q35164008-4B1896B7-0DDD-4375-8CA3-E8E4DA0143F1

P304

Q35164008-37022F8C-2077-4B3B-9488-DD4577491609

P31

Q35164008-C84E8F23-2BA7-4B50-84B0-857C021CCD38

P356

Q35164008-785A0D22-B949-4349-9865-634D5E7E4FEB

P407

Q35164008-61072AA8-9CA7-476E-881F-45DD94C15179

P433

Q35164008-725C8B11-EB03-476E-9215-72B286E986B4

P478

Q35164008-09659079-91F8-4009-AAED-68F30C6C6891

P50

Q35164008-A68E0DBA-39ED-4BF8-ABD1-45047B1AF1CC

P577

Q35164008-BDF2745F-89FA-4031-8E13-DE26A02F54D4

P5875

Q35164008-0E6D5985-583B-4B94-BCE4-795B6A28AF9B

P698

Q35164008-002CD5C2-F3DE-4B36-8F1E-148C7C68F542

P932

Q35164008-3D4AB1EA-26C1-4840-9002-D053A0403119

P356

J.GASTRO.2010.10.056

P1433

Gastroenterology

P1476

Protease inhibitor-resistant h ...... production of infectious virus

@en

P2093

Christoph Welsch

http://www.w3.org/2001/XMLSchema#string

Daisuke Yamane

http://www.w3.org/2001/XMLSchema#string

David R McGivern

http://www.w3.org/2001/XMLSchema#string

Minkyung Yi

http://www.w3.org/2001/XMLSchema#string

Stanley M Lemon

http://www.w3.org/2001/XMLSchema#string

Tetsuro Shimakami

http://www.w3.org/2001/XMLSchema#string

P2860

Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells

A novel recombinant single-chain hepatitis C virus ns3-ns4a protein with improved helicase activity

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

NS3 Helicase Domains Involved in Infectious Intracellular Hepatitis C Virus Particle Assembly

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase

P304

667-675

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2010.10.056

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47699984

http://www.w3.org/2001/XMLSchema#string

P698

21056040

http://www.w3.org/2001/XMLSchema#string

P932

3155954

http://www.w3.org/2001/XMLSchema#string